# Submitting Continuous Glucose Monitoring Data in Clinical Trials - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/submitting-continuous-glucose-monitoring-data-in-clinical-trials/242cfeef-dde5-46f4-b50e-9669a5a75ca9

> FDA guidance document: Submitting Continuous Glucose Monitoring Data in Clinical Trials. Issue date: May 06, 2026. Get complete insights and analysis.

---

## Details

- Title: Submitting Continuous Glucose Monitoring Data in Clinical Trials
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2026-05-06
- Last Changed: 2026-05-07
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6821">FDA-2017-D-6821</a>

## Related Documents

- [Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-clinical-trial-datasets-and-documentation-for-clinical-outcome-assessments-using-item-response-theory/9895a301-585a-4b74-83a1-3b526f3ec3d3)
- [Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-nonclinical-datasets-for-evaluation-of-rodent-carcinogenicity-studies-of-pharmaceuticals/5558f50a-6637-45c7-9848-23f5e55738d6)
- [Submitting Patient-Reported Outcome Data in Cancer Clinical Trials](https://www.globalkeysolutions.net/guidances/guidance-document/submitting-patient-reported-outcome-data-in-cancer-clinical-trials/cdd19350-5c19-44b6-9812-51398fa0fc71)